Beta-galactosyl-umbelliferone-labeled hapten conjugates
AssigneeMiles Laboratories, Inc.
InventorsRobert C. Boguslaski, John F. Burd, Robert J. Carrico
Life of this patent
Estimating the term…
Loading patent…
AssigneeMiles Laboratories, Inc.
InventorsRobert C. Boguslaski, John F. Burd, Robert J. Carrico
Estimating the term…
An improved specific binding assay method and reagent for determining a ligand in a liquid medium employing, as an enzyme-cleavable substrate label, a residue having the formula: G--D--R wherein G is a glycone, D is a dye indicator moiety, and R is a linking group through which the label residue is covalently bound to a binding component of a conventional binding assay system, such as the ligand, an analog thereof, or a specific binding partner thereof. The monitored characteristic of the label is the release of a detectable product, usually a fluorogen or chromogen, upon enzymatic cleavage of the glycosidic linkage between the glycone and the dye indicator moiety. The assay method may follow a homogeneous or heterogeneous format. The preferred glycone is a .beta.-galactosyl group and the preferred dye indicator moiety is an umbelliferone residue. The improved assay is particularly suited to the determination of haptens, such as drugs, and antigenic proteins and polypeptides, including antibodies, following a homogeneous competitive binding assay format. CROSS-REFERENCE TO RELATED APPLICATION
A .beta.-galactosyl-umbelliferone-labeled theophylline conjugate of the formula:
A .beta.-galactosyl-umbelliferone-labeled phenobarbital conjugate of the formula:
A .beta.-galactosyl-umbelliferone-labeled carbamazepine conjugate of the formula:
A .beta.-galactosyl-umbelliferone-labeled primidone conjugate of the formula:
A .beta.-galactosyl-umbelliferone-labeled hapten conjugate of the formula:
Dependencies are inferred from the claim text.